Corrona Registries: Psoriatic Arthritis and Spondyloarthritis
Corrona launched the Psoriatic Arthritis and Spondyloarthritis (PsA/SpA) Registry in March 2013 under the direction of Dr. Philip Mease.
Corrona's goal was to create a unique cohort of PsA/SpA patients using the RA registry model. Objectives include understanding the epidemiology and natural history of Spondyloarthritis conditions including psoriatic arthritis, comorbidities, prescribing practices, and comparative effectiveness. In general, clinical trials provide safety data on new treatments for 6 to 12 months, but the long-term safety profiles of agents remain unclear. As new drugs are approved for PsA/SpA, there is a growing need for an independent registry that will collect long-term real world data on safety, comorbidities, and quality of life.
The Corrona PsA/SpA Registry is a prospective, multi-center, observational disease-based registry. TAEs and AEs of special interest such as MACE, malignancies and infections are collected.
Interested participants who are 18 years of age or older who meet eligibility criteria are eligible to participate. Questionnaires are completed by patients and their physicians at routine clinical visits every 6 months.
If you are a rheumatologist interested in being involved in the PsA/SpA Registry, please contact us at: email@example.com. If you are a patient interested in participating in this registry, please contact your rheumatologist to see if they are a participating site.
As with all Corrona registries, subscribers to the Corrona PsA/SpA Registry may request that Corrona collect additional data elements based upon their specific scientific or commercial needs.